0001104659-24-004549.txt : 20240117
0001104659-24-004549.hdr.sgml : 20240117
20240117172051
ACCESSION NUMBER: 0001104659-24-004549
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240113
FILED AS OF DATE: 20240117
DATE AS OF CHANGE: 20240117
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Mandelia Ashish
CENTRAL INDEX KEY: 0001782805
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38129
FILM NUMBER: 24539360
MAIL ADDRESS:
STREET 1: 840 MEMORIAL DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Mersana Therapeutics, Inc.
CENTRAL INDEX KEY: 0001442836
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 840 MEMORIAL DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-498-0020
MAIL ADDRESS:
STREET 1: 840 MEMORIAL DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: MERSANA THERAPEUTICS INC
DATE OF NAME CHANGE: 20080813
4
1
tm243529-6_4seq1.xml
OWNERSHIP DOCUMENT
X0508
4
2024-01-13
0
0001442836
Mersana Therapeutics, Inc.
MRSN
0001782805
Mandelia Ashish
C/O MERSANA THERAPEUTICS, INC.
840 MEMORIAL DRIVE
CAMBRIDGE
MA
02139
0
1
0
0
VP, Chief Accounting Officer
1
Common Stock
2024-01-13
4
M
0
2645
0
A
18218
D
Common Stock
2024-01-14
4
M
0
4783
0
A
23001
D
Common Stock
2024-01-15
4
M
0
4519
0
A
27520
D
Common Stock
2024-01-15
4
M
0
833
0
A
28353
D
Common Stock
2024-01-16
4
S
0
5025
2.71
D
23328
D
Restricted Stock Unit
2024-01-13
4
M
0
2645
0
D
Common Stock
2645
7938
D
Restricted Stock Unit
2024-01-14
4
M
0
4783
0
D
Common Stock
4783
9566
D
Restricted Stock Unit
2024-01-15
4
M
0
4519
0
D
Common Stock
4519
4519
D
Restricted Stock Unit
2024-01-15
4
M
0
833
0
D
Common Stock
833
0
D
Stock Option (Right to Buy)
3.02
2024-01-15
4
A
0
75000
0
A
2034-01-14
Common Stock
75000
75000
D
Restricted Stock Unit
2024-01-15
4
A
0
16667
0
A
Common Stock
16667
16667
D
Represents shares of common stock received upon vesting of a portion of the restricted stock units ("RSUs") awarded to the Reporting Person on January 13, 2023.
Includes 4,000 shares of common stock acquired by the Reporting Person on June 15, 2023 and 599 shares of common stock acquired by the Reporting Person on December 15, 2023, in each case through the Issuer's employee stock purchase plan.
Represents shares of common stock received upon vesting of a portion of the RSUs awarded to the Reporting Person on January 14, 2022.
Represents shares of common stock received upon vesting of a portion of the RSUs awarded to the Reporting Person on January 15, 2021.
Represents shares of common stock received upon vesting of a portion of the RSUs awarded to the Reporting Person on January 15, 2020.
Represents the sale of shares of common stock to satisfy the Reporting Person's tax withholding obligations in connection with the service-based vesting and settlement of the RSUs pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 10, 2023. The sale was effected through an automatic "sell to cover" transaction that did not represent a discretionary trade by the Reporting Person.
The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $2.70 to $2.71, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Each RSU represents the contingent right to receive one share of common stock of the Issuer.
25% of the total number of RSUs granted vested on January 13, 2024, and the remainder shall vest thereafter in equal annual installments over the next three years.
25% of the total number of RSUs granted vested on January 14, 2024, and the remainder shall vest thereafter in equal annual installments over the next two years.
25% of the total number of RSUs granted vested on January 15, 2024, and the remainder shall vest on January 15, 2025
Fully vested as of January 15, 2024.
The option shall vest in equal quarterly installments over four years from the date of grant.
The RSUs shall vest in equal annual installments over four years from the date of grant.
/s/ Alejandra Carvajal, Attorney-in-Fact
2023-01-17